Summary
Treatment of the older patients with T2DM can be complex given that these patients often have advanced T2DM, multiple comorbidities, and need combination therapy. This article presents the results of a double-blind phase 3 study of the sodium-glucose cotransporter 2 inhibitor canagliflozin in patients aged 55 to 80 years.
- Diabetes Mellitus
- Hyperglycemia/Hypoglycemia
- Diabetes & Endocrinology Clinical Trials
- Diabetes Mellitus
- Endocrinology
- Diabetes & Metabolic Syndrome
- Hyperglycemia/Hypoglycemia
- Diabetes & Endocrinology Clinical Trials
- © 2014 MD Conference Express®
Tools
Long-term Canagliflozin is Efficacious and Generally Well Tolerated in Older Patients
Permalink:
Table of contents
Cited By...
- No citing articles found.